Objectives: This study investigated the influence of virological response (VR) to entecavir on clinical liver disease progression in nucleos(t)ide analogue (NA)-naive and -experienced patients.
Introduction
Hepatitis B virus (HBV) infection is a major health problem, with an estimated prevalence of 350 million carriers worldwide. Each year HBV infection is responsible for more than 1 million deaths from cirrhosis and hepatocellular carcinoma (HCC). 1 The risk of progression to cirrhosis and HCC, and liver-related mortality, are strongly correlated with serum HBV DNA levels, and a reduction in HBV DNA to undetectable levels has been adopted as an important endpoint for antiviral efficacy in patients with chronic hepatitis B (CHB). 2 -6 Entecavir is a potent antiviral agent superior to lamivudine and adefovir for hepatitis B virological suppression. 7 -9 Suppression of HBV DNA replication to undetectable levels was observed in 92% of treatment-naive patients positive for hepatitis B e antigen (HBeAg), and genotypic resistance to entecavir is rare in nucleos(t)ide analogue (NA)-naive patients throughout 5 years of treatment. 10 -12 Moreover, long-term entecavir therapy has been shown to improve fibrosis in patients with CHB. 11 -13 However, limited data are available on the effect of virological response (VR) to entecavir on the incidence of major clinical events such as HCC, decompensation and death in patients undergoing long-term entecavir therapy. A recent study demonstrated that VR to entecavir is associated with a lower probability of disease progression in patients with cirrhosis. 14 However, this study did not investigate the role of VR to entecavir in reducing the risk of disease progression separately according to NA-naive or NA-experienced patients. 14 The role of VR in reducing the risk of liver disease progression may differ according to NA experience. Furthermore, a previous review study demonstrated that achievement of VR did not seem to significantly reduce the HCC risk in patients with lamivudine resistance treated with adefovir with or without continued lamivudine. 15 However, the benefit of VR for clinical events or HCC in patients with prior lamivudine-or adefovir-resistant mutants treated with entecavir monotherapy was not reported.
The aim of this study was to investigate whether the role of VR to entecavir in predicting clinical liver disease progression or HCC differs between NA-naive and NA-experienced patients, particularly in those who have had prior NA-resistant mutants during entecavir therapy.
Patients and methods

Patients
From August 2006 to May 2010, 487 consecutive CHB patients who received entecavir monotherapy were analysed retrospectively. Inclusion criteria consisted of seropositivity for hepatitis B surface antigen (HBsAg) for at least 6 months, a viral load of at least 2000 IU/mL at the initiation of entecavir and duration of entecavir therapy of at least 12 months. Patients were excluded if they exhibited any evidence of autoimmune hepatitis, alcoholic liver disease or viral coinfections [hepatitis C virus (HCV), hepatitis D virus (HDV) or HIV]. Patients were excluded if they had HCC at baseline or if HCC occurred during the first 6 months of entecavir therapy. Of the 487 subjects, 323 were NA-naive and 164 had received prior lamivudine or adefovir treatment.
A liver ultrasound scan was performed every 3 -6 months and an ultrasound scoring system for liver surface, parenchyma, vascular structure and spleen size was used to describe the severity of hepatic parenchymal damage. 16, 17 Cirrhosis was diagnosed by: (i) liver biopsy histology or (ii) combined repeated ultrasound findings suggestive of cirrhosis from at least two examinations performed a minimum of 6 months apart with clinical features such as splenomegaly, thrombocytopenia, oesophageal varices, ascites or hepatic encephalopathy. The diagnosis of HCC was based on: (i) histopathological findings of tumour tissues; or (ii) one typical HCC feature on a dynamic image or serum a-fetoprotein (AFP) levels .200 ng/mL if the nodule was .2 cm in cirrhotic liver; or (iii) two typical HCC features on dynamic images if the nodule was between 1 and 2 cm in a cirrhotic liver. 18 This study was approved by the Ethics Committee of Chang Gung Memorial Hospital and each patient provided informed consent.
Methods
All patients were followed up every 12 weeks throughout therapy. Supplementary weekly or twice-weekly visits were scheduled if alanine aminotransferase (ALT) levels were increasing more than five times the upper limit of the normal range (ULN; 40 U/L). Follow-up studies consisted of clinical assessment, conventional liver biochemical tests and measures of serological hepatitis B marker levels (including HBeAg and anti-HBe). Each patient was assessed for HBV DNA quantitatively prior to therapy and every 6 months during treatment or at the time of biochemical breakthrough.
Genotypic analysis was performed: (i) in NA-experienced patientsusing serum stored at the end of all prior NA treatments if serum HBV DNA was ≥300 copies/mL; (ii) in NA-naive subjects -using serum stored at the entecavir baseline if entecavir-resistant mutations were detected during entecavir treatment; or (iii) for all patients -in case of virological breakthrough during entecavir monotherapy or if serum HBV DNA ≥300 copies/mL was observed at the end of follow-up.
Definitions
Virological response was defined as a serum HBV DNA level ,300 copies/mL during entecavir treatment.
11 VR-6 and VR-12 were defined as VR achieved at month 6 and 12, respectively. For non-cirrhotic and compensated cirrhotic patients at baseline, clinical events were defined as a composite of development of hepatic decompensation [jaundice (serum bilirubin level ≥3 mg/dL), new development of variceal bleeding, ascites or encephalopathy], new HCC, death or liver transplantation. 14 For patients with decompensated cirrhosis at baseline, clinical events were defined as recurrent hepatic decompensation (new or recurrent development of jaundice, varices bleeding, ascites or encephalopathy after clinical remission during entecavir treatment), new HCC, death or liver transplantation.
Biochemical breakthrough was defined as an ALT level of more than twice the ULN during continued treatment in patients who initially had normalization of ALT. Virological breakthrough was defined as an increase in serum HBV DNA levels of ≥1 log 10 copies/mL from nadir.
Serology
The presence of HBsAg, HBeAg, anti-HCV antibodies and anti-HDV antibodies was determined using commercial assay kits [HBsAg enzyme immunoassay (EIA; Abbott, North Chicago, IL, USA); HBeAg EIA (Abbott); anti-HCV EIA 3.0 (Abbott); anti-HDV radioimmunoassay (Abbott)]. Serum HBV DNA levels were determined using a quantitative real-time PCR assay, the COBAS AmpliPrep-COBAS TaqMan HBV test (CAP-CTM; Roche Molecular Systems Inc., Branchburg, NJ, USA), with a lower detection limit of 12 IU/mL (70 copies/mL).
Detection of HBV-resistant mutants in HBV polymerase genes
The viral mutational analysis was performed by LiPA assay (Innogenetics NV, Gent, Belgium). LiPA DR version 2 and version 3 were used to identify the amino acids at codons rt173, rt180, rt204 and rt184, rt202, rt250, respectively.
HBV genotyping
The HBV genotypes in sera were determined using restriction fragment length polymorphism analysis of the S-gene sequence, amplified by PCR with nested primers, as previously described. 19, 20 
Data analysis
Data are displayed as means+standard deviation (SD), proportions or medians (range). On comparing the values between two groups, the x 2 test was used to analyse categorical variables, and Student's t-test and the Mann-Whitney U-test were applied for continuous variables with normal and skewed distributions, respectively. Cumulative incidences of VR, clinical events and HCC were determined using the Kaplan-Meier method using a log-rank test. Univariate and multivariate analyses were performed to identify factors associated with clinical events and HCC development, including baseline characteristics and VR during entecavir therapy, using Cox proportional hazards regression models. All statistical tests were two-sided, and a P value of ,0.05 was considered statistically significant.
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Results
Baseline characteristics of the study population
Baseline characteristics of the study population are shown in Table 1 . NA-experienced patients were more often men and had lower serum total bilirubin levels and prothrombin time at baseline compared with NA-naive patients. Sixty-two (37.8%) and 25 (15.2%) NA-experienced patients had a history of genotypic resistance to lamivudine and adefovir, respectively.
The study population consisted of 314 patients with CHB without cirrhosis, 152 patients with compensated cirrhosis, and 21 patients with decompensated cirrhosis. Overall median follow-up duration for the study population was 36 (12 -73) months.
Predictive factors for developing clinical events and HCC for all patients
Forty-nine patients in the study population developed clinical events during entecavir therapy. Of these, 10 developed an episode of hepatic decompensation, 36 developed HCC and 3 died (2 from hepatic failure and 1 from oesophageal variceal bleeding). The cumulative probabilities of developing clinical events at months 12, 24, 36 and 48 were 0.3%, 1%, 1.8% and 5.1% for non-cirrhotic patients, respectively; 1.4%, 9.2%, 15.4% and 22.3% for compensated cirrhotic patients, respectively; and 23.8%, 38.5% and 49.7% (no subject had follow-up for 4 years) for decompensated cirrhotic patients, respectively (P,0.001, Figure 1a ). The cumulative probabilities of developing HCC at months 12, 24, 36 and 48 were 0%, 0.7%, 1.9% and 3.8% for non-cirrhotic patients, respectively; 0.7%, 5.7%, 11.2% and 19.1% for compensated cirrhotic patients, respectively; and 14.3%, 28.9%, 34.4% and 34.4% for decompensated cirrhotic patients, respectively (P,0.001, Figure 1b) . Patients with decompensated cirrhosis had the highest incidence of developing clinical events and HCC during entecavir therapy. The cumulative probabilities of developing clinical events and HCC at months 12, 24, 36 and 48 were 0.05% and 0%, 1% and 0.05%, 1% and 0.05%, and 2.8% and 0.05% for naive non-cirrhotic patients, respectively. The cumulative probabilities of developing clinical events and HCC at months 12, 24, 36 and 48 were 1.7% and 0.08%, 10% and 6.7%, 27.4% and 13.1%, and 26.3% and 23.2% for naive cirrhotic patients, respectively. Yang et al.
The baseline factors and the achievement of VR during entecavir treatment were analysed for association with clinical events (Table 2 ) and HCC (Table 3) . Cox regression analysis showed that age, baseline cirrhosis, pre-treatment ALT level ≤200 U/L, albumin level, platelet count and non-achievement of VR during entecavir treatment were independent predictors for clinical events (Table 2) . Age, baseline cirrhosis, pre-treatment ALT level ≤200 U/L, albumin level and non-achievement of VR were predictive of HCC (Table 3) . VR during entecavir treatment remained an independent predictor for clinical events and HCC after excluding decompensated cirrhotic patients.
Of the 487 patients, 25 (1 naive, 24 NA-experienced) developed entecavir resistance during entecavir therapy. There was no significant difference in terms of developing clinical events and HCC between patients with and without occurrence of entecavir resistance (Tables 2 and 3 ).
Predictive factors for developing clinical events and HCC for NA-experienced patients
The baseline factors and the achievement of VR during entecavir treatment for NA-experienced patients were analysed for association with clinical events (Table 4) and HCC (Table 5) . Cox regression analysis showed that baseline cirrhosis, HBeAg-negative status, pre-treatment HBV DNA level, prothrombin time and nonachievement of VR during entecavir treatment were independent predictors for clinical events (Table 4) . Age, baseline cirrhosis and non-achievement of VR were independent predictors for HCC (Table 5) .
Effect of VR on clinical events or HCC in NA-naive and NA-experienced patients
The cumulative probabilities of achieving a VR at months 12, 24, 36 and 48 were 74%, 95.2%, 98% and 98% in NA-naive patients, respectively, and 55.5%, 79.9%, 83.3% and 83.3% in NA-experienced patients, respectively (P,0.001). NA-experienced patients had a lower rate of VR than NA-naive patients [hazard ratio (HR) 1.47; 95% CI 1.19-1.82; P,0.001] after adjusting for age, ALT levels, HBeAg status and HBV DNA at baseline.
For all patients, the cumulative incidences of clinical events and HCC development according to VR during entecavir therapy are shown in Figure 2 . In non-cirrhotic patients, the incidence of clinical events (HR 0.15, 95% CI 0.03-0.80) and HCC development (HR 0.08, 95% CI 0.01 -0.50) was lower in patients with VR than in those without VR. In cirrhotic patients, the incidence of clinical events (HR 0.15, 95% CI 0.03 -0.80) and HCC development (HR 0.21, 95% CI 0.07 -0.60) was lower in patients with VR compared with in those without VR.
Because the rate of VR was different between NA-naive and NA-experienced patients, we compared the influence of VR on the risk of developing clinical events and HCC in both groups. 
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In NA-naive patients, no significant difference was noted between patients with and without VR for clinical events and HCC development in non-cirrhotic and cirrhotic patients. All 30 NA-naive patients who developed clinical events (including 23 cases of HCC) did so after achieving VR. Furthermore, early VR at month 6 or 12 was not a significant predictor for developing clinical events and HCC in NA-naive patients either with or without cirrhosis. In NA-experienced patients, the cumulative incidences of clinical events and HCC development according to VR during entecavir therapy are shown in Figure 3 . There was a significant difference between patients with and without VR for clinical events and HCC development in non-cirrhotic patients (clinical events and HCC: HR 0.10, 95% CI 0.01-0.77) and cirrhotic patients (clinical events: HR 0.15, 95% CI 0.05 -0.44; HCC: HR 0.13, 95% CI 0.03-0.49). In addition, VR at month 12 of entecavir therapy (VR-12) was also significantly predictive for clinical events (P ¼ 0.035 and P¼ 0.007 by log-rank test in non-cirrhotic and cirrhotic patients, respectively) and HCC (P ¼ 0.035 and P ¼ 0.005 in non-cirrhotic and cirrhotic patients, respectively) in NA-experienced patients. Furthermore, VR-12 was also an independent predictor for clinical events (HR 0.15, 95% CI 0.06-0.40, P,0.001) and HCC (HR 0.17, 95% CI 0.05 -0.54, P ¼ 0.003) after adjusting for other baseline factors (except VR during entecavir therapy) in NA-experienced patients. By contrast, VR at month 6 was not a significant predictor for developing clinical events and HCC in NA-experienced patients either with or without cirrhosis. All risk factors included in Table 2 were analysed. In non-cirrhotic patients, multivariate analysis showed that lower pre-treatment HBV DNA levels (increase per 1 log copies/mL; HR 0.48, 95% CI 0.25-0.93, P¼0.029) and VR (HR 0.034, 95% CI 0.003-0.474, P¼0.012) were independent predictors for clinical events and HCC development. In cirrhotic patients, only VR during entecavir therapy was an independent predictor for developing clinical events (HR 0.15, 95% CI 0.05-0.44, P¼0.001) and HCC (HR 0.13, 95% CI 0.03-0.49, P¼0.003).
Effect of VR on clinical events or HCC in different subgroups of NA-experienced patients
Of the 164 NA-experienced patients, 92 had no prior lamivudine or adefovir resistance, 62 had prior lamivudine-resistant mutants and 25 had prior adefovir-resistant mutants (15 had adefovir-resistant mutations after switching to adefovir sequential monotherapy for lamivudine-resistant CHB). The rates of VR, clinical events and HCC development in the three subgroups are presented in Figure 4 . Compared with naive patients, VR rates were not decreased by NA experience in those who never developed lamivudine-or adefovir-resistant mutants (P ¼ 0.33 by log-rank test). By contrast, patients with prior lamivudine-or adefovir-resistant mutants were significantly associated with reduced VR rates (P,0.001). In patients who had never developed lamivudine-or adefovir-resistant mutants, VR to Yang et al.
entecavir was not a significant predictor for the development of clinical events and HCC. By contrast, in patients with lamivudine-resistant mutants, lack of VR to entecavir was an independent predictor for the development of clinical events and HCC after adjusting for other baseline factors. In patients with adefovir-resistant mutants, lack of VR to entecavir was an independent predictor for the development of clinical events after adjusting for other baseline factors, but not for HCC (Figure 4) .
Discussion
In the large randomized trial described by Liaw et al., 21 in which CHB patients with advanced fibrosis or cirrhosis were included, long-term lamivudine monotherapy was shown to reduce the risk of liver disease progression and HCC in the absence of genotypic resistance compared with placebo. Another study showed that in HBeAg-negative patients, long-term lamivudine treatment significantly improved survival and reduced the risk of major complications compared with interferon treatment in patients without sustained response or untreated patients. 22 There was a trend for better major-event-free survival in patients remaining in VR than in those with virological breakthrough or no response to lamivudine. 22 Thus, CHB patients receiving NA therapy had a significantly lower incidence of liver-related complications and HCC than untreated patients. Furthermore, maintenance of VR was important because patients developing lamivudine resistance were at increased risk of developing liverrelated complications and HCC. 15,21 -23 A recent study reported significant beneficial effects of VR to entecavir in preventing liver disease progression in CHB patients with cirrhosis.
14 However, the study did not investigate the role of VR in reducing the risk of liver disease progression separately according to NA-naive or NA-experienced patients. 14 In the present study, our data showed the beneficial effects of VR to entecavir in preventing liver disease progression in those both with and without cirrhosis. Furthermore, VR to entecavir reduced the probability of developing clinical events and HCC in NA-experienced patients but not in NA-naive patients. This difference is probably caused by the relatively small number of NA-naive patients who did not achieve VR (3.4%, 11/323), making it impossible to perform statistically robust comparisons. In addition, most of the NA-naive patients without VR were positive for HBeAg and had high HBV DNA levels at baseline. These patients were younger and did not have cirrhosis, and had a relatively low risk of developing clinical events and HCC. In our study, all 30 NA-naive patients who developed clinical events (including 23 cases of HCC) did so after achieving VR. Thus, achieving early VR during entecavir treatment did not completely eliminate the risk of clinical events and HCC in NA-naive patient, and such patients should be continuously monitored for clinical events and HCC, especially those with cirrhosis.
However, we found that VR was significantly associated with a lower probability of clinical events and HCC in both Virological response to entecavir and liver disease 2159 JAC non-cirrhotic and cirrhotic NA-experienced CHB patients. Previous studies have shown that the antiviral efficacy of entecavir is significantly decreased in patients with lamivudine-resistant mutations. 24 In our study, 37.8% (62/164) of NA-experienced patients had a prior history of lamivudine resistance. Of these, only 59.7% (37/62) achieved VR during entecavir therapy. Our study showed that VR to entecavir was the most important independent predictor for clinical disease progression and HCC in NA-experienced patients after adjusting for other baseline factors, particularly in patients with pre-existing cirrhosis.
We further investigated the effect of VR on clinical outcome in the different subgroups of NA-experienced patients. We did not show a significant effect of VR as a predictor for clinical outcome in NA-experienced patients who had not developed lamivudine-or adefovir-resistant mutants. However, patients without VR during entecavir therapy were at increased risk of developing liver-related complications and HCC if they were NA-experienced patients with lamivudine-or adefovir-resistant mutants. A previous review study demonstrated that achievement of VR did not seem to significantly reduce the HCC risk in patients with lamivudine resistance treated with adefovir with or without continued lamivudine. 15 Our result is not compatible with previous studies. The benefit of VR for reducing the liver disease progression or HCC risk seems to be different in patients with lamivudine resistance who received adefovir with or without lamivudine or entecavir rescue therapy.
A previous study suggested that early monitoring of VR to NA therapy in NA-naive patients is essential to identify cases of suboptimal response at week 24 or 48 in order to modify the subsequent therapy accordingly. 6, 25 However, it remained unclear whether early VR to entecavir at week 24 or 48 could predict clinical outcomes. In our study, we found that achieving a VR at month 12 (but not at month 6) was an effective predictor for clinical disease progression and HCC in NA-experienced patients. By contrast, VR at month 6 or 12 was not a significant predictor for clinical disease progression and HCC in NA-naive patients. Early VR to entecavir at month 6 was therefore not a useful predictor in NA-naive or -experienced patients. However, multivariate analysis showed that achieving a VR during entecavir therapy (but not VR-12) was an independent predictor for clinical events and HCC development (Tables 2 and 3) . Considering these results, it is important to note that a delayed VR to entecavir over 12 months is still useful for reducing the risk of clinical disease progression and HCC in NA-experienced patients. We suggest that adding or shifting to other appropriate antiviral agents to achieve VR in NA-experienced patients who did not achieve a VR at or beyond month 12 under entecavir treatment is important in reducing the risk of clinical disease progression and HCC.
It is interesting to note that in our study, a higher pretreatment ALT level (.200 IU/L) was an independent protective factor against clinical events and HCC. The rate of pre-treatment ALT (≤200 U/L) was observed more frequently in cirrhotic patients than non-cirrhotic patients (42.4% versus 23.7%, Yang et al. P ≤ 0.001). This might partially explain how a higher ALT at baseline would be protective against clinical events. However, it remains unclear what mechanism lies behind the association between a higher ALT and the decreased risk of clinical events, even after adjusting for other factors.
In conclusion, our study suggests that VR during entecavir therapy was associated with a reduced risk of clinical liver Virological response to entecavir and liver disease 2161 JAC disease progression and HCC only in NA-experienced patients who had prior lamivudine-or adefovir-resistant mutants, but not in NA-naive patients or NA-experienced patients who had never developed lamivudine-or adefovir-resistant mutants. However, only a relatively small number of NA-naive patients and NA-experienced patients without lamivudine-or adefovirresistant mutants did not achieve VR, which limited the power of the statistical analysis among both subgroups. VR to entecavir at month 12 (but not early VR at month 6) remained a significant predictor associated with the development of clinical events and HCC in NA-experienced patients.
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